Industry Developments
United Kingdom
BMI View: GlaxoSmithKline (GSK)'s Q411 results highlight the company's high exposure to healthcare sector cost-containment programmes and pricing pressures placed on medicines by governments...
2012-02-08France
BMI View: Despite concerted progress made on the fiscal consolidation front in the first half of 2011, the French government's medium-term fiscal targets remain on the optimistic side,...
2012-02-07United Kingdom
BMI View: The continued global generic competition to Nexium (esomeprazole) and the upcoming patent expiry for Seroquel (quetiapine) (March 2012 in the US) will test AstraZeneca's strength...
2012-02-06Ireland
BMI View: The Irish pharmaceutical industry contributed to 26% of total commodity exports in 2010, equating to US$31.03bn. R&D invesment in Ireland, combined with strong export-directed...
2012-01-26Belgium
BMI View: Belgium's ageing population will have an unprecedented effect on the demand for pharmaceuticals and healthcare, which is a positive for companies operating in the industry....
2012-01-25Italy
BMI View: The Italian pharmaceutical market continues to be a challenging proposition and BMI believes the sector will be a target of further cost containment in 2012, particularly...
2012-01-24Spain
BMI View: Reinforcing BMI's view that companies with significant exposure to debt-ridden European markets will be hard hit by government austerity measures across the region, and in...
2012-01-20Germany
BMI View: Despite the threat of austerity measures and the government's focus on cost-containment within the pharmaceuticals and healthcare sector, as well as the impact of generic...
2012-01-18
